TY - JOUR
T1 - Significance of High-Containment Biological Laboratories Performing Work During the COVID-19 Pandemic
T2 - Biosafety Level-3 and -4 Labs
AU - Yeh, Kenneth B.
AU - Tabynov, Kairat
AU - Parekh, Falgunee K.
AU - Mombo, Illich
AU - Parker, Kyle
AU - Tabynov, Kaissar
AU - Bradrick, Shelton S.
AU - Tseng, Ashley S.
AU - Yang, Ji Rong
AU - Gardiner, Lolly
AU - Olinger, Gene
AU - Setser, Bradly
N1 - Publisher Copyright:
© Copyright © 2021 Yeh, Tabynov, Parekh, Mombo, Parker, Tabynov, Bradrick, Tseng, Yang, Gardiner, Olinger and Setser.
PY - 2021/8/13
Y1 - 2021/8/13
N2 - High containment biological laboratories (HCBL) are required for work on Risk Group 3 and 4 agents across the spectrum of basic, applied, and translational research. These laboratories include biosafety level (BSL)-3, BSL-4, animal BSL (ABSL)-3, BSL-3-Ag (agriculture livestock), and ABSL-4 laboratories. While SARS-CoV-2 is classified as a Risk Group 3 biological agent, routine diagnostic can be handled at BSL-2. Scenarios involving virus culture, potential exposure to aerosols, divergent high transmissible variants, and zoonosis from laboratory animals require higher BSL-3 measures. Establishing HCBLs especially those at BSL-4 is costly and needs continual investments of resources and funding to sustain labor, equipment, infrastructure, certifications, and operational needs. There are now over 50 BSL-4 laboratories and numerous BSL-3 laboratories worldwide. Besides technical and funding challenges, there are biosecurity and dual-use risks, and local community issues to contend with in order to sustain operations. Here, we describe case histories for distinct HCBLs: representative national centers for diagnostic and reference, nonprofit organizations. Case histories describe capabilities and assess activities during COVID-19 and include capacities, gaps, successes, and summary of lessons learned for future practice.
AB - High containment biological laboratories (HCBL) are required for work on Risk Group 3 and 4 agents across the spectrum of basic, applied, and translational research. These laboratories include biosafety level (BSL)-3, BSL-4, animal BSL (ABSL)-3, BSL-3-Ag (agriculture livestock), and ABSL-4 laboratories. While SARS-CoV-2 is classified as a Risk Group 3 biological agent, routine diagnostic can be handled at BSL-2. Scenarios involving virus culture, potential exposure to aerosols, divergent high transmissible variants, and zoonosis from laboratory animals require higher BSL-3 measures. Establishing HCBLs especially those at BSL-4 is costly and needs continual investments of resources and funding to sustain labor, equipment, infrastructure, certifications, and operational needs. There are now over 50 BSL-4 laboratories and numerous BSL-3 laboratories worldwide. Besides technical and funding challenges, there are biosecurity and dual-use risks, and local community issues to contend with in order to sustain operations. Here, we describe case histories for distinct HCBLs: representative national centers for diagnostic and reference, nonprofit organizations. Case histories describe capabilities and assess activities during COVID-19 and include capacities, gaps, successes, and summary of lessons learned for future practice.
KW - BSL-3
KW - BSL-4
KW - COVID-19
KW - biosecurity
KW - high containment biological laboratory
UR - http://www.scopus.com/inward/record.url?scp=85114273904&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114273904&partnerID=8YFLogxK
U2 - 10.3389/fbioe.2021.720315
DO - 10.3389/fbioe.2021.720315
M3 - Article
AN - SCOPUS:85114273904
SN - 2296-4185
VL - 9
JO - Frontiers in Bioengineering and Biotechnology
JF - Frontiers in Bioengineering and Biotechnology
M1 - 720315
ER -